REG - RTW Biotech Opp. - Total Voting Rights

RTW Biotech OpportunitiesAnnouncement

01/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240501:nRSA6783Ma&default-theme=true

RNS Number : 6783M  RTW Biotech Opportunities Ltd  01 May 2024

LEI: 549300Q7EXQQH6KF7Z84

01 May 2024

RTW Biotech Opportunities Ltd
(the "Company")

Total Voting Rights

In accordance with the FCA's Disclosure Guidance and Transparency Rule
5.6.1R the Company would like to notify the market of the following:

At the close of business on 30 April 2024, the Company had 394,290,303
Ordinary shares in issue, of which 9,603,791 were held in Treasury.
Therefore, the total number of voting rights in the Company was 384,686,512**.

The above figure of 384,686,512 may be used by Shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.

**As per the "Completion of Acquisition" announcement published on 13 February
2024, the denominator used for the NAV per share calculation will exclude the
48,322,863 New RTW Bio Shares issued to RTW Biotech Opportunities Operating
Ltd in respect of its shareholding in Arix held by the Company.

For Further Information:

 

 RTW Investments, LP                           +44 (0)20 7959 6361
 Woody Stileman, Managing Director

 Krisha McCune, Director, Investor Relations

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREBLFXZZLEBBZ